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Background:  Atherosclerotic peripheral artery disease (PAD) is common and results in 
limitations in quality of life and potential progression to limb loss.  Options for therapy 
include medical therapy, supervised exercise, surgical revascularization, and more 
recently, endovascular therapies to restore arterial perfusion to the limb.   
Endovascular revascularization has evolved over the past two decades, from 
percutaneous transluminal angioplasty (PTA) to self-expanding stents, atherectomy, laser 
angioplasty, and drug eluting stents. Despite impressive technologic advances, PTA 
remains the standard of care at many institutions and is the recommended primary 
treatment modality for femoral-popliteal PAD according to current ACCF/AHA 
guidelines. However, restenosis after PTA is common. Therefore, a significant clinical 
need remains for a device that is able to achieve more durable patency than PTA but does 
not require a permanent implant. 
 Drug coated balloons (DCB) have the potential to address this need. Several 
randomized controlled clinical trials of PTA balloons coated with different formulations 
of paclitaxel have been conducted in Europe
1,2,3,4
 and demonstrated more durable efficacy 
than PTA with comparable safety. These studies were limited by small sample sizes and 
powered solely for an angiographic primary endpoint. The pivotal LEVANT 2 trial was 
designed in collaboration with the United States (US) Food and Drug Administration 
(FDA) to demonstrate safety and efficacy in a large population and to obtain US FDA 
approval.  
Methods:  A prospective, multicenter, single blind, trial comparing the Lutonix® 
drug coated balloon vs. PTA for treatment of femoropopliteal PAD   (LEVANT 2) is 
the first US based 2:1 randomized controlled trial of 476 patients with femoral-popliteal 
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PAD designed to demonstrate superior efficacy and non-inferior safety of a novel 
paclitaxel DCB compared to PTA. The primary efficacy endpoint is primary patency at 
12 months. The primary safety endpoint is composite freedom at 12 months from peri-
operative death, index limb amputation, re-intervention, and limb-related mortality.  A 
series of important secondary endpoints include physical functioning, quality of life, 
revascularizations, and alternative measures of patency. In order to minimize bias 
potential for confounding variables, LEVANT 2: 
(1) excluded patients stented after predilation prior to randomization; 
(2) incorporated very stringent criteria for bailout stenting; 
(3) did not count bailout stenting as a TLR or failure of any endpoint 
(4) required a blinded clinician to perform up clinical evaluations at follow up and 
(5) required clinical assessment prior to review of duplex ultrasound results.  
Conclusions:  LEVANT 2 represents the first US-inclusive multicenter, randomized, 
controlled trial to assess the safety and efficacy of a novel drug coated balloon (DCB) 
compared to PTA as primary therapy for symptomatic PAD on the background of 
standard medical therapy. 
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Background 
PAD is a prevalent, world wide problem, affecting ~5-18% of the adult 
population depending on age
5
 and income status
6
.  Although a significant proportion of 
patients with PAD have no reported symptoms from the syndrome
7
, many patients 
experience disabling inability to walk or, in advanced cases, may suffer limb loss.
8
  With 
the global epidemic of diabetes mellitus, particularly among the elderly
9
, it is anticipated 
that more severe manifestations of PAD will become more prevalent
10
.   
The cornerstone of management of PAD is medical therapy.  Antiplatelet therapy 
is commonly offered to patients with PAD
11
.  Exercise, either supervised
12
 or performed 
independently
13
 has demonstrated significant improvement in physical function, quality 
of life and walking distances, even when compared to revascularization
14
.  Because of 
lack of patient compliance, revascularization remains popular.  Surgical revascularization 
is no longer the first line treatment for most patients with PAD due to the associated 
morbidity and mortality associated with these procedures
11
.   
Technology has advanced the field of revascularization for patients with PAD 
over many years, allowing patients with intermittent claudication and CLI to undergo 
endovascular procedures as an initial therapeutic strategy. PTA was initially widely 
performed, but 12-month primary patency rates of 28-37%
15
 reduced the enthusiasm for 
PTA.  Stents, which initially were used when procedural complications of PTA occurred, 
offered superior outcomes particularly for self-expanding stents
16
.  Subsequently, several 
studies demonstrated that primary use of stents offered improved patency than PTA 
alone
17,18
.   
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As stent use continued, reports of stent fracture began to emerge, raising questions 
about the durability of these metallic implants
19
.  Longer follow up of these devices 
suggested a direct causal relationship between fracture and loss of patency
20
.  Newer 
generation stents resulted in lower fracture rates
21
.  Based upon the dramatic efficacy of 
anti-proliferative drug coating on coronary stents, and despite initial failure of similar 
devices in the femoropopliteal segments
22
, a randomized trial comparing a drug coated 
self expanding stent demonstrated superiority over PTA
23
.  Finally, treatment of in-stent 
restenosis is particularly problematic.    
PTA is still the first line standard-of-care at many institutions, and it remains the 
primary treatment recommendation of the American College of Cardiology and American 
Heart Association (ACC/AHA) guideline for management of patients with 
femoropopliteal PAD
24
, with stent used only “as salvage therapy for a suboptimal or 
failed result from balloon dilatation.”    
DCB have the potential to improve options by delivering an anti-restenotic agent 
to the peripheral arteries while avoiding a permanently implanted metallic scaffold. 
Multiple randomized controlled clinical trials of PTA balloons coated with various 
formulations of paclitaxel have been conducted in Europe
25,26,27,28
.  All of these studies, 
including this study’s precursor LEVANT 1, were of limited sample size and powered 
only to evaluate an angiographic primary endpoint at 6 months. Each demonstrated 
treatment with DCB resulted in significantly less late lumen loss (the primary endpoint) 
with safety comparable to standard PTA.  
The pivotal LEVANT 2 IDE trial was designed to demonstrate safety and efficacy 
of DCB in a large population including US centers and to obtain device FDA approval. 
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Several limitations of historic femoropopliteal studies were carefully considered during 
this process. For example, in devices studies it is often not possible for the 
interventionalist to be blinded to treatment group: both stents and DCBs look and 
feel different than conventional PTA. This limitation makes it difficult to avoid bias 
from clinical assessments performed by unblinded investigators in follow-up.  
Furthermore, it is a subjective decision whether or not to perform a target lesion 
revascularization (TLR) in cases where symptoms are worsening or restenosis is 
observed on imaging. The impact of this potential bias was observed in several 
studies; for example, of subjects with restenosis documented by angiography in the 
THUNDER study, the decision to reintervene (TLR) was made by the unblinded 
physician in only 29% of DCB cases but 95% of control PTA cases1.  Another 
potential source of unintentional bias was apparent in historic studies that counted 
bail-out stenting as an immediate primary endpoint failure29,30. In RESILIENT29 and 
ZILVER PTX30 the test group had a 40 and 50% primary endpoint advantage over 
control immediately following the index procedure. In PTA studies, differences in 
bailout stenting, for example 4% vs. 22% (p = 0.02) in THUNDER,1 may also 
confound interpretation primary outcomes. The LEVANT 2 trial was designed with 
these historic limitations in mind. 
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Methods 
A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial 
Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for 
Treatment of Femoropopliteal Arteries, LEVANT 2 is a multicenter, single blind, 2:1 
randomized, controlled trial comparing outcomes after treatment of symptomatic PAD 
with paclitaxel-coated (DCB) vs. uncoated PTA balloons. The study hypothesis is that 
DCB will provide superior patency and non-inferior safety compared to PTA.  
The trial was conducted at 55 centers located in the United States and Europe.  
The first subject was enrolled on July 20, 2011 and last subject enrolled on July 10, 2012. 
The trial is in compliance with the International Conference on Harmonization Good 
Clinical Practice, ISO 14155, and Declaration of Helsinki. One-year follow-up has been 
completed, and study follow-up, monitoring, and adjudications are ongoing through 5 
years. 
Study Population 
Eligible patients have symptomatic claudication or ischemic rest pain (Rutherford 
category 2-4) with an angiographically significant atherosclerotic lesion (>70% diameter 
stenosis) in the superficial femoral and/or popliteal arteries and a patent outflow artery to 
the foot.  Total target lesion length per patient is ≤15 cm and reference vessel diameter is 
4 to 6 mm.  Inclusion and exclusion criteria are provided in Table 1.  
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Study Device 
The Lutonix DCB® (Bard Lutonix, New Hope, Minnesota, USA) is an 0.035” 
guidewire compatable PTA catheter with a semi-compliant balloon that is coated with 
paclitaxel at a concentration of 2 µg/mm
2
.  Paclitaxel is a well-known and widely used 
anti-proliferative agent, with its’ mechanism associated with prevention of mitosis.  The 
Lutonix DCB coating includes excipient polysorbate and sorbitol to facilitate drug release 
and tissue deposition. Pre-clinical
26
 and pilot randomized clinical data
25
 support safety, 
efficacy, and feasibility of use to treat femoropopliteal arteries.  Balloon sizes included in 
the study are 4.0-6.0 mm in diameter and 40-100 mm in length.   
Study Objectives and endpoints 
The primary objective of the study is to demonstrate the superior efficacy and 
non-inferior safety of DCB compared to uncoated PTA for treatment of stenosis or 
occlusion of the femoropopliteal arteries. The primary safety endpoint is the composite of 
freedom from all-cause perioperative (≤30 day) death and freedom at 1 year from the 
following: index limb amputation (above or below the ankle), index limb re-intervention, 
and index-limb-related death. The primary efficacy endpoint is primary patency of the 
target lesion at 1 year. Primary patency is defined as the absence of target lesion 
restenosis (adjudicated by a blinded duplex ultrasosonography core laboratory based on 
peak systolic velocity ratio (DUS PSVR) ≥2.5) and freedom from target lesion 
revascularization (TLR). 
Planned secondary endpoints are detailed in Table 2 and include procedural 
success, revascularizations, alternative thresholds for DUS patency, and change over time 
in clinical and quality of life measures.  
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Sample Size and Statistical Considerations 
The pre-specified analysis population includes all evaluable randomized patients.  
The primary proportion-based analysis is based on events through the close of the 12 
month follow-up window on day 395.  Sensitivity analyses are conducted in order to 
assess the potential impact of missing data, including tipping point, worst case, and 
Kaplan-Meier time-to-event analyses.  
Expected outcomes for sample size calculations were based on 6 month results 
observed in the LEVANT 1 trial extrapolated to 12 months (70% vs. 48% for safety and 
59% vs. 42% for efficacy).  The sample size is based on primary efficacy, for which 405 
evaluable patients provides 90% power for superiority based on a two-sided α = 0.05 
likelihood ratio chi-square tests of binomial proportions. Randomization of 476 patients 
accounted for an expected 15% loss of patients from the primary, as observed in recent 
studies of similar populations.
29,30
  This sample size provides > 95% power for the 
primary safety endpoint based on a one-sided α = 0.025 Farrington-Manning test of 
binomial proportions with a 5% non-inferiority margin.  
For analysis of demographics and secondary outcomes, continuous variables are 
compared using t-tests and Wilcoxon nonparametric tests for means and categorical 
variables are compared using χ2 for proportions. 
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Study Procedure 
Enrollment and Randomization: Patients signed informed consent, underwent 
screening, ankle-brachial index determination, walking impairment questionnaire, and a 
six-minute hall walk test
31
.  Arteriography was performed to confirm angiographic 
inclusion criteria are met (lesion location, length, run-off).  Patients meeting entry criteria 
were required to have a protocol defined pre-dilatation before randomization to study 
treatments.  The pre-dilation balloon was a standard PTA balloon inflated to a diameter 
approximately 1 mm less than the reference vessel diameter.  Following pre-dilatation, 
patients that were likely to require a stent based on strict angiographic criteria (major 
flow-limiting dissection or > 70% residual stenosis) were treated and not randomized in 
order to minimize this confounding variable. Patients unlikely to require a stent based on 
angiographic assessment after predilation were randomized 2:1 to Lutonix DCB or 
control PTA. (Figure 1).  Balloons were sized to target 100% of reference vessel diameter 
and have length sufficient to treat 5mm proximal and distal to the target lesion and the 
predilated segment (including overlap of multiple balloons). For patients randomized to 
DCB, balloons were inflated for as long as necessary to achieve a satisfactory procedural 
result. Since drug delivery occurs on the first inflation, two DCBs must be deployed to 
treat longer lesions. A minimum overlap of at least 5mm was required to ensure drug 
delivery to the entire segment. For subjects randomized to the control arm, treatment was 
performed with uncoated PTA catheter(s).  Use of cutting/scoring balloons was not 
allowed.  Control PTA balloons may be deflated and repositioned to treat longer lesions.  
 Bailout stenting was allowed in both treatment groups only if the following 
criteria were met after treatment and prolonged (≥ 2 min ) post-dilatation: residual 
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stenosis >50% or major flow-limiting dissection AND a translesional pressure gradient 
>20mmHg (using ≤4F end-hole catheter) or >10mmHg (pressure wire) is measured 
immediately distal to the target lesion. 
After angioplasty, all patients were treated with dual antiplatelet therapy for at 
least one month and aspirin indefinitely.  
Follow-up procedures: All randomized subjects are to return at 1, 6, 12 and 24 
month intervals for laboratory testing (complete blood count, metabolic panel), ankle 
brachial index, Rutherford class assessment, six minute walk test, walking impairment 
and quality of life questionnaires, and DUS. A pharmacokinetic substudy was conducted 
in a subset of DCB-treated patients in order to assess serum paclitaxel exposure over 
time. At 6, 12, and 24-months, the clinical status of the subject was assessed prior to 
performing (or reviewing, if technician already completed) the required DUS (for 
assessment of patency). A physician other than the one who performed the index 
procedure must conduct the clinical assessments.  
Study management and AE Adjudication 
Lutonix, a subsidiary of CR Bard, is the study sponsor and has overall 
responsibility for the conduct of the study. Two independent contract research 
organizations (Prairie Education and Research Cooperative, IL, and Genae 
associates, BE) are engaged to provide study site management and monitoring of all 
case report forms in the US and EU, respectively. Statistical analyses were performed 
by independent biostatisticians from NAMSA Medical Research. The study sponsor is 
responsible for ensuring that the study meets all applicable regulatory requirements 
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and good clinical practices, and the CROs are responsible for clinical events 
committee (CEC) and data monitoring committee (DMC) management.  The 
principal investigators are actively involved in the assessment of site performance 
and contact sites directly to improve compliance. The steering committee has final 
responsibility for scientific conduct and contractual rights to publish the primary 
results independent of the trial outcome. 
The clinical trial is designed in accordance with Good Clinical Practices (GCP), 
HIPAA requirements, and applicable laws of various governing bodies. Data are 
collected in accordance with the Guidance for Industry on the collection of race and 
ethnicity data in clinical trials.  
The LEVANT 2 study was expected to complete enrollment within 12 months of 
first patient enrolled.  A single roll-in case was to be performed at each clinical site in 
order to train site personnel in proper procedure and data collection.  Roll-in subjects 
were required to meet all protocol requirements (including enrollment criteria and follow-
up). The LEVANT 2 trial includes angiographic (Synvacor, Prairie Education and 
Research Cooperative, Springfield, IL) and duplex ultrasonography (Vascore, 
Massachusetts General Hospital, Boston, MA) core laboratories.  Vascular technologists 
who performed the required DUS were provided with hands-on duplex ultrasound 
training by the core laboratory.   
A data monitoring committee, composed of physician experts in peripheral 
vascular disease or cardiovascular medicine, and biostatisticians who were not 
participating in the trial and had no affiliation with Lutonix, regularly reviewed and 
evaluated aggregate subject data to ensure continued safety, validity and scientific merit 
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of the trial. All adverse events, including non-serious events, are reviewed and 
adjudicated by an independent CEC composed of 3 clinicians who are experts in the field 
of vascular intervention or cardiovascular medicine and were not participants or 
investigators in the study. The CEC members are blinded to subject treatment.   
No extramural funding was used to support this work.  Employees of 
Bard/Lutonix did provide statistical support for the trial and those segments of this 
manuscript, however the authors are solely responsible for the drafting and editing of this 
manuscript and it’s final contents.   
Discussion 
LEVANT 2 is the first femoropopliteal device trial that (1) excluded patients 
stented after predilation prior to randomization, (2) incorporated very stringent criteria for 
bailout stenting, (3) does not count bailout stenting as a TLR or failure of any endpoint, 
(4) required a blinded clinician to perform up clinical evaluations at follow up, and (5) 
required clinical assessment prior to review of DUS images. These design elements were 
intended to minimize potential sources of unintentional bias that may confound 
interpretation of historic stent and drug coated balloons trials.   
Another source of potential bias occurs with unblinded clinical follow-up 
assessment. It is a subjective decision whether or not to reintervene in cases of worsening 
symptoms or in cases where restenosis is observed on imaging. The LEVANT 2 protocol 
therefore requires that both the subject and the investigator conducting the follow-up visit 
be blinded to treatment until the completion of the 12 month visit. Furthermore, since 
reinterventions may be driven by imaging data rather than worsening of clinical 
symptoms, the clinical status of the subject is to be assessed prior to reviewing the 
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imaging data. These LEVANT 2 design elements remove the potential for subjective bias 
at follow-up to affect one year outcomes.  
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Table 1- Subject Inclusion/Exclusion Criteria 
INCLUSION  EXCLUSION  
Clinical Criteria 
1. Male or non-pregnant female ≥18 years of age;  
2. Rutherford Clinical Category 2-4;  
3. Patient is willing to provide informed consent, is 
geographically stable and comply with the required 
follow up visits, testing schedule and medication 
regimen; 
 
Angiographic Criteria 
Lesion Criteria 
4. Length ≤15 cm; 
5. Up to two focal lesions or segments within the 
designated 15 cm length of vessel may be treated (e.g. 
two discrete segments, separated by several cm, but 
both falling within a composite length of <15 cm); 
6. ≥70% stenosis by visual estimate; 
7. Lesion location starts ≥1 cm below the common 
femoral bifurcation and terminates distally ≤2 cm 
below the tibial plateau AND  ≥1 cm above the origin 
of the TP trunk; 
8. de novo lesion(s) or non-stented restenotic lesion(s) 
>90 days from prior angioplasty procedure; 
9. Lesion is located at least 3 cm from any stent, if target 
vessel was previously stented;  
10. Target vessel diameter between ≥4 and ≤6 mm and 
able to be treated with available device size matrix; 
11. Successful, uncomplicated (without use of a crossing 
device) antegrade wire crossing of lesion; 
12. A patent inflow artery free from significant lesion 
(≥50% stenosis) as confirmed by angiography 
(treatment of target lesion acceptable after successful 
treatment of inflow artery lesions);  
13. NOTE: Successful inflow artery treatment is defined 
as attainment of residual diameter stenosis ≤30% 
without death or major vascular complication. 
14. At least one patent native outflow artery to the ankle, 
free from significant (≥50%) stenosis as confirmed by 
angiography that has not previously been 
revascularized (treatment of outflow disease is NOT 
permitted during the index procedure); 
15. Contralateral limb lesion(s) cannot be treated within 2 
weeks before and/or planned 30 days after the 
protocol treatment in order to avoid confounding 
complications; 
16. No other prior vascular interventions within 2 weeks 
before and/or planned 30 days after the protocol 
treatment. 
 
Patients will be excluded if ANY of the following 
conditions apply:  
1. Pregnant or planning on becoming pregnant or 
men intending to father children; 
2. Life expectancy of <5 years; 
3. Patient is currently participating in an 
investigational drug or other device study or 
previously enrolled in this study; 
NOTE: Enrollment in another clinical trial 
during the follow up period is not allowed. 
4. History of hemorrhagic stroke within 3 
months; 
5. Previous or planned surgical or interventional 
procedure within 2 weeks before or within 30 
days after the index procedure; 
6. History of MI, thrombolysis or angina within 
2 weeks of enrollment;  
7. Rutherford Class 0, 1, 5 or 6; 
8. Renal failure or chronic kidney disease with 
MDRD GFR ≤30 ml/min per 1.73 m2 (or 
serum creatinine ≥2.5 mg/L within 30 days of 
index procedure or treated with dialysis); 
9. Prior vascular surgery of the index limb, with 
the exception of remote common femoral 
patch angioplasty separated by at least 2 cm 
from the target lesion; 
10. Inability to take required study medications or 
allergy to contrast that cannot be adequately 
managed with pre- and post-procedure 
medication; 
11. Anticipated use of IIb/IIIa inhibitor prior to 
randomization; 
12. Ipsilateral retrograde access; 
13. Composite lesion length is >15 cm or there is 
no normal proximal arterial segment in which 
duplex flow velocity can be measured; 
14. Significant inflow disease. Successful 
treatment of inflow disease allowed prior to 
target lesion treatment; 
15. Known inadequate distal outflow (>50 % 
stenosis of distal popliteal and/or all three 
tibial vessels), or planned future treatment of 
vascular disease distal to the target lesion; 
16. Sudden symptom onset, acute vessel 
occlusion, or acute or sub-acute thrombus in 
target vessel; 
17. Severe calcification that renders the lesion un-
dilatable; 
18. Use of adjunctive treatment modalities (i.e. 
laser, atherectomy, cryoplasty, scoring/cutting 
balloon, etc.). 
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Table 2- Secondary Endpoints 
Safety  Efficacy  
 Freedom at 30 days from all-cause death, 
index limb amputation above the ankle and 
target vessel revascularization (TVR) (VIVA 
Safety Endpoint)  
 Composite of freedom from all-cause 
perioperative (≤30 day) death and freedom 
from the following at 1, 6, 24, 36, 48, and 60 
months: index limb amputation, index limb 
re-intervention, and index-limb-related death. 
 
The following endpoints will be assessed at 1, 
6, 12, 24, 36, 48 and 60 months: 
 All-cause death  
 Amputation (above the ankle)-Free Survival 
(AFS)  
 Target Vessel Revascularization (TVR)  
 Reintervention for treatment of thrombosis of 
the target vessel or embolization to its distal 
vasculature  
 Major vascular complications 
 Readmission for cardiovascular events 
 Acute Device, Technical and Procedural 
success  
The following endpoints will be assessed 
at 6, 12 and 24 Months: 
 Primary and Secondary Patency (DUS 
PSVR <2.5) 
 Alternative Primary and Secondary 
Patency based on alternative definitions 
of DUS PSVR <2.0 and <3.0 
 DUS Clinical Patency (DUS PSVR <2.5 
without prior Clinically Driven TLR) 
 Target Lesion Revascularization (TLR) 
o Clinically-driven 
o Total (clinical and 
DUS/angiography-driven) 
 Change of Rutherford classification 
from baseline 
 Change of resting Ankle Brachial Index 
(ABI) from  baseline 
 Change in Walking Impairment 
Questionnaire from baseline 
 Change in Six Minute Walk Test from 
baseline in a subset of patients 
 Change in quality of life from baseline, 
as measured by EQ-5D and SF36-v2 
surveys 
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Figure 1-Study Overview 
 
 
 
Post-Predilatation Lesion Criteria
Baseline Angiogram
Test Arm
Dilatation with Drug 
Coated Balloon
Control Arm
Dilatation with uncoated 
balloon
Defined Pre-Dilatation
(Balloon inflated to ~1mm <RVD)/
Enrollment
Randomization
2:1
Defined bailout stenting
(if necessary) with FDA approved Stent. 
Standard Post-Dilatation per physician 
discretion.
Subjects followed for 
Safety through 30 days 
and withdrawn
Recruitment
Major Flow Limiting Dissection
-OR- 
Residual Stenosis >70%
Residual Stenosis ≤70% and Absence of Flow-Limiting 
Dissection
-OR-
Lesion is not appropriate for stenting due to proximity to 
the knee joint
Treat per Standard Practice or
No additional Treatment required
